Fig. 2.

A Comparison of the Evidence Favoring the AHA/ACC and ESC/EAS Approach to the Three Key Questions

Abbreviations: AHA – American Heart Association; ACC – American College of Cardiology; ESC – European Society of Cardiology; EAS – European Atherosclerosis Society; ASCVD – Atherosclerotic Cardiovascular Disease; LDL-C – Low-Density Lipoprotein Cholesterol; REDUCE-IT – Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial; DECLARE-TIMI 58 – Dapaglifozin and Cardiovascular Outcomes in Type 2 Diabetes Trial; 1˚- Primary; 2° - Secondary; IMPROVE-IT – Improved Reduction of Outcomes: Vytorin Efficacy International Trial; TIMI – Thrombolysis In Myocardial Infarction; CABG – Coronary Artery Bypass Graft; PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitor; Rx – Prescriptions; ARR – Absolute Risk Reduction; FOURIER – Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects with Elevated Risk; ODDYSEY OUTCOMES – Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome During Treatment with Alirocumab; CAC – Coronary Artery Calcium; SCCT – Society of Cardiovascular Computed Tomography; MACE – Major Adverse Cardiovascular Events.